Clinical Development,Clinical Operations,News

Overcoming the Challenges of Decentralised Trials

4 weeks ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin

Decentralised trials – clinical trials with virtual or online elements – have a huge number of advantages in the trial space. They are cheaper, faster, and allow for greater safety and recruitment of patients. But so far they have yet to see a positive uptake in big pharma companies, despite technology for virtual form-filling, wearable monitoring systems and online patient check-ins all existing and highly affordable for pharma companies.

To clarify the area for professionals who need to know, Proventa International created a White Paper on decentralised and virtual trials, looking at the innovations and trends shaping 2020, the technologies available to pharma companies, and the biggest challenges facing these new trials and how to overcome them. Below is just a sample of the full White Paper: to read the larger report, click here.

If you are unable to see the PDF below, please click here.

For more information on future events, including the upcoming Clinical OperationsCTSC and Pharmacovigilance meetings in November 2020, click here.

Joshua Neil, Editor
Proventa International

More news

Weekly News Round-up – 11/9/20

In the news this week, Oxford University and AstraZeneca have temporarily suspended their joint COVID-19 vaccine trials over safety fears as a subject falls ill. In other news, GSK and Sanofi begin their own COVID trials, and a group of...

1 week ago
Clinical Development,Clinical Operations,News

Weekly News Round-up – 11/9/20

In the news this week, Oxford University and AstraZeneca have temporarily suspended their joint COVID-19 vaccine trials over safety fears as a subject falls ill. In other news, GSK and Sanofi begin their own COVID trials, and a group of...

1 week ago

How will COVID-19 Change Biomanufacturing?

The COVID-19 pandemic proved how ill-equipped the world was for a virus of that scale and potency. In the first months of the pandemic, businesses across all sectors scrambled to prepare their processes and supply chains for the coming disruption,...

2 weeks ago
Clinical Development,Clinical Operations,News

How will COVID-19 Change Biomanufacturing?

The COVID-19 pandemic proved how ill-equipped the world was for a virus of that scale and potency. In the first months of the pandemic, businesses across all sectors scrambled to prepare their processes and supply chains for the coming disruption,...

2 weeks ago

Why the Decline in Pharma R&D?

For a few decades now there has been a narrative in the pharmaceutical sector that R&D productivity has been steadily declining: thanks to a lack of low-hanging fruit, blockbuster drugs have been harder and harder to find. AI promises a...

4 weeks ago
Clinical Development,Clinical Operations,News

Why the Decline in Pharma R&D?

For a few decades now there has been a narrative in the pharmaceutical sector that R&D productivity has been steadily declining: thanks to a lack of low-hanging fruit, blockbuster drugs have been harder and harder to find. AI promises a...

4 weeks ago
Working With us

Interested?
Reserve your space